Biofrontera

Biofrontera Net Income

The Net Income of Biofrontera (BFRI) as of Nov 10, 2026 is -10.54 M USD. In the previous year, Net Income was -17.76 M USD — a change of -40.67% (higher).

Net Income

-10.54 MUSD

YoY

-40.67%

Last updated:

In 2025, Biofrontera's profit amounted to -10.54 M USD, a -40.67% increase from the -17.76 M USD profit recorded in the previous year.

The Biofrontera Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Income
Date
Net Income
Jan 1, 2023
-20.13 M USD
Jan 1, 2024
-17.76 M USD
Jan 1, 2025
-10.54 M USD
Jan 1, 2026 (e)
-2.10 M USD
Jan 1, 2027 (e)
5.01 M USD
Jan 1, 2028 (e)
2.21 M USD
Jan 1, 2029 (e)
3.61 M USD
Jan 1, 2030 (e)
6.76 M USD
The Biofrontera Net Income history
YEARNet IncomeYoY
est6.76 MUSD+87.10%
est3.61 MUSD+63.16%
est2.21 MUSD-55.81%
est5.01 MUSD-338.89%
est-2.10 MUSD-80.10%
-10.54 MUSD-40.67%
-17.76 MUSD-11.78%
-20.13 MUSD+3,045.47%
-640,000.00USD-98.30%
-37.71 MUSD+243.25%
-10.99 MUSD+0.05%
-10.98 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Revenue

Biofrontera Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
35.16 M USD
-15.66 M USD
-17.76 M USD
Jan 1, 2025
41.25 M USD
-9.15 M USD
-10.54 M USD
Jan 1, 2026 (e)
46.15 M USD
-3.49 M USD
-2.10 M USD
Jan 1, 2027 (e)
53.47 M USD
4.00 M USD
5.01 M USD
Jan 1, 2028 (e)
68.36 M USD
3.85 M USD
2.21 M USD
Jan 1, 2029 (e)
86.40 M USD
5.62 M USD
3.61 M USD
Jan 1, 2030 (e)
109.18 M USD
9.60 M USD
6.76 M USD
Jan 1, 2031 (e)
112.46 M USD
0.00 USD
0.00 USD

Biofrontera Margins

Biofrontera stock margins

The Biofrontera margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biofrontera. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biofrontera.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
53.18 %
-44.55 %
-50.51 %
Jan 1, 2025
79.52 %
-22.18 %
-25.54 %
Jan 1, 2026 (e)
79.52 %
-7.56 %
-4.54 %
Jan 1, 2027 (e)
79.52 %
7.48 %
9.37 %
Jan 1, 2028 (e)
79.52 %
5.64 %
3.24 %
Jan 1, 2029 (e)
79.52 %
6.51 %
4.18 %
Jan 1, 2030 (e)
79.52 %
8.80 %
6.19 %
Jan 1, 2031 (e)
79.52 %
0.00 %
0.00 %

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera Inc generates revenue through the commercialization of pharmaceutical products for dermatological conditions. The company's primary product Ameluz, a prescription drug used with the BF-RhodoLED lamp series for photodynamic therapy, treats actinic keratoses on the face and scalp. Ameluz is sold in the United States for lesion-directed and field-directed treatment of mild-to-moderate actinic keratoses. The company also markets Xepi, a topical antibiotic for impetigo treatment in adults and children two months and older, targeting bacterial skin infections caused by Staphylococcus aureus or Streptococcus pyogenes. Both products are licensed and sold directly to healthcare providers and pharmacies. Biofrontera's revenue streams come from the sale of Ameluz and Xepi to U.S. healthcare providers and pharmacies. The company focuses on dermatological treatments, specifically addressing actinic keratoses and impetigo. Ameluz is used in combination with the BF-RhodoLED lamp series, creating a bundled solution for photodynamic therapy. Xepi serves as a standalone topical antibiotic for impetigo, a common skin infection. The company's target customers include dermatologists and pediatricians who treat skin conditions in adult and pediatric patients. The company's business model centers on licensed pharmaceutical products, with Ameluz and Xepi as its core offerings. Ameluz is used for photodynamic therapy of actinic keratoses, while Xepi targets impetigo infections. Both products are prescribed in the United States for specific dermatological conditions, with Ameluz requiring the BF-RhodoLED lamp series for full treatment. The company's revenue is derived from direct sales of these products to healthcare providers and pharmacies, focusing on the U.S. market for dermatological treatments. Biofrontera is one of the most popular companies on Eulerpool.

Net Income Details

Understanding Biofrontera's Profit Margins

The profit margins of Biofrontera represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Biofrontera's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Biofrontera's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Biofrontera's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Biofrontera’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Biofrontera stock

Net Income of Biofrontera is -10.54 M USD in 2025.

Net Income of Biofrontera changed from -17.76 M USD to -10.54 M USD, representing a -40.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Income Biofrontera since 2006 – with annual values, charts, and detailed analysis.

The achievement of a profit is the biggest goal of a company. The profit can be used for distribution or reinvestment. The profit (also called annual surplus or EAT, earnings after taxes) is the positive difference between income and expenses in a period as shown in the income statement. A negative annual surplus is called annual loss. Both performance measures are also combined under the neutral term annual result.

The Net Income is derived from all revenues / sales minus the expenses in the period under review. The following overview clearly shows which positions contribute to the annual surplus and where the differences lie compared to other variants of profit such as EBT, EBIT, and EBITDA.

Net Income's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Income's Biofrontera historically and in real time.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Biofrontera

All Key Metrics — Biofrontera